Humana Inc.

Fundamentals5.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Modest FY profitability
  • Elevated leverage
  • Q4 cash/earnings loss

AI
AI Summary

6.0

Humana has shifted from a Medicare-advantage-growth story to a binary, execution-dependent turnaround where near-term value hinges on rapid medical-cost improvement and a timely rebound in Stars bonuses—if those two variables show clear stabilization the stock can re-rate, but continued cost/claims volatility and elevated leverage will drive swift downside. Monitor quarterly medical-cost trends, Stars filings/trajectory, and liquidity/reserve swings (reclaiming the 21-day SMA/~176.7 would signal stabilization; failure to hold ~163 would likely extend losses).

StarsRecovery
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Modest FY profitability
  • Elevated leverage
  • Q4 cash/earnings loss

Mixed fundamentals: modest full‑year profitability and solid liquidity are outweighed by elevated leverage, thin operating margins and a sharp Q4 cash/earnings loss that raises short‑term execution risk.

ExecutionRisk
WatchLiquidity

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below SMA
  • Lower highs
  • Elevated volatility

Over the last month HUM fell ~10.6% to $169.90 and sits ~3.8% below its ~$176.7 short-term SMA—short-term bearish, with resistance at $187–$191 and support near $163–$166; breaking $163.67 would widen downside while reclaiming the SMA would signal stabilization.

bearish
Support Level: $163.67–$166.00
Resistance Level: $187.00–$191.00

~10.6% decline and ~15% intra-window swing over the last month indicating elevated volatility

Sentiment & News

6.0

Key News Insights:

  • Rising medical costs
  • 4‑STAR membership drop
  • $1B debt issued

Humana faces near-term margin pressure from rising medical costs and a steep drop in 4‑STAR Medicare Advantage members while management pursues STAR mitigation, CenterWell growth, Medicaid expansion and debt financing to drive a turnaround by bonus year 2028.

operational_headwinds
turnaround

Near-term earnings and stock volatility likely persist, but strategic actions (STAR fixes, CenterWell, Medicaid) could stabilize margins by 2028 if execution and membership trends improve